Allogene Therapeutics Management
Management criteria checks 2/4
Allogene Therapeutics' CEO is David Chang, appointed in Jun 2018, has a tenure of 6.58 years. total yearly compensation is $14.06M, comprised of 5.1% salary and 94.9% bonuses, including company stock and options. directly owns 3.68% of the company’s shares, worth $14.06M. The average tenure of the management team and the board of directors is 1.9 years and 6.8 years respectively.
Key information
David Chang
Chief executive officer
US$14.1m
Total compensation
| CEO salary percentage | 5.1% |
| CEO tenure | 6.6yrs |
| CEO ownership | 3.7% |
| Management average tenure | 1.9yrs |
| Board average tenure | 6.8yrs |
Recent management updates
Recent updates
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
Dec 10Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Nov 22
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Aug 27Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$283m |
| Jun 30 2024 | n/a | n/a | -US$279m |
| Mar 31 2024 | n/a | n/a | -US$292m |
| Dec 31 2023 | US$14m | US$724k | -US$327m |
| Sep 30 2023 | n/a | n/a | -US$344m |
| Jun 30 2023 | n/a | n/a | -US$365m |
| Mar 31 2023 | n/a | n/a | -US$361m |
| Dec 31 2022 | US$15m | US$724k | -US$340m |
| Sep 30 2022 | n/a | n/a | -US$313m |
| Jun 30 2022 | n/a | n/a | -US$308m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$10m | US$695k | -US$182m |
| Sep 30 2021 | n/a | n/a | -US$251m |
| Jun 30 2021 | n/a | n/a | -US$239m |
| Mar 31 2021 | n/a | n/a | -US$229m |
| Dec 31 2020 | US$8m | US$675k | -US$316m |
| Sep 30 2020 | n/a | n/a | -US$243m |
| Jun 30 2020 | n/a | n/a | -US$227m |
| Mar 31 2020 | n/a | n/a | -US$207m |
| Dec 31 2019 | US$11m | US$600k | -US$185m |
| Sep 30 2019 | n/a | n/a | -US$154m |
| Jun 30 2019 | n/a | n/a | -US$147m |
| Mar 31 2019 | n/a | n/a | -US$240m |
| Dec 31 2018 | US$13m | US$362k | -US$212m |
Compensation vs Market: David's total compensation ($USD14.06M) is above average for companies of similar size in the US market ($USD2.22M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Chang (64 yo)
6.6yrs
Tenure
US$14,061,848
Compensation
Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7.2yrs | US$9.36m | 2.92% $ 11.2m | |
| Co-Founder | 6.6yrs | US$14.06m | 3.68% $ 14.1m | |
| Co-Founder & Director | no data | US$684.49k | 0.14% $ 551.6k | |
| Executive VP & Chief Technical Officer | 1.8yrs | US$5.80m | 0.13% $ 483.1k | |
| Executive VP of Research & Development and Chief Medical Officer | 2yrs | US$8.13m | 0.018% $ 69.7k | |
| Executive VP & CFO | 1.3yrs | no data | 0.54% $ 2.1m | |
| Senior VP | less than a year | no data | no data | |
| Senior VP | 1.4yrs | no data | 0.21% $ 817.8k | |
| Chief People Officer | 2.7yrs | no data | no data | |
| Executive VP | 2yrs | no data | no data | |
| Senior Vice President of Finance | no data | no data | 0.042% $ 161.8k | |
| Secretary | no data | no data | no data |
1.9yrs
Average Tenure
58.5yo
Average Age
Experienced Management: ALLO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 7.2yrs | US$9.36m | 2.92% $ 11.2m | |
| Co-Founder | 6.6yrs | US$14.06m | 3.68% $ 14.1m | |
| Co-Founder & Director | 7.2yrs | US$684.49k | 0.14% $ 551.6k | |
| Independent Director | 6.8yrs | US$585.00k | 0.15% $ 559.7k | |
| Independent Director | 6.8yrs | US$510.00k | 0.12% $ 465.1k | |
| Member of Scientific Advisory Board | 5.7yrs | no data | no data | |
| Independent Director | 6.8yrs | no data | no data | |
| Independent Director | 6.3yrs | US$495.00k | 0.075% $ 286.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.8yrs | no data | no data |
6.8yrs
Average Tenure
64.5yo
Average Age
Experienced Board: ALLO's board of directors are considered experienced (6.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 05:45 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Allogene Therapeutics, Inc. is covered by 33 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |